Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease

• Published in: PloS one Vol. 10; no. 3; p. e0119452
• Main Authors: Graham, Stewart F, Chevallier, Olivier P, Elliott, Christopher T, Hölscher, Christian, Johnston, Janet, McGuinness, Bernadette, Kehoe, Patrick G, Passmore, Anthony Peter, Green, Brian D
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24-03-2015; Public Library of Science (PLoS)
• Subjects: Acetonitrile; Aged; Aging; Alzheimer Disease - blood; Alzheimer's disease; Arginine; Arginine - blood; Biomarkers; Biomarkers - blood; Blood; Blood plasma; Brain research; Case-Control Studies; Chemometrics; Clinical trials; Cognitive ability; Cognitive Dysfunction - blood; Database searching; Dementia; Development and progression; Diabetes; Diagnosis; Disease control; Enrichment; Female; Food security; Health care; Humans; Impairment; Male; Mass Spectrometry; Mass spectroscopy; Mathematical models; Medical research; Memory; Metabolism; Metabolites; Metabolomics; Methods; Nitriles; Patients; Physiological aspects; Polyamines; Polyamines - blood; Predictive Value of Tests; Public health; Statistical models; Studies; United Kingdom > UK
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0119452

This study combined high resolution mass spectrometry (HRMS), advanced chemometrics and pathway enrichment analysis to analyse the blood metabolome of patients attending the memory clinic: cases of mild cognitive impairment (MCI; n = 16), cases of MCI who upon subsequent follow-up developed Alzheimer's disease (MCI_AD; n = 19), and healthy age-matched controls (Ctrl; n = 37). Plasma was extracted in acetonitrile and applied to an Acquity UPLC HILIC (1.7μm x 2.1 x 100 mm) column coupled to a Xevo G2 QTof mass spectrometer using a previously optimised method. Data comprising 6751 spectral features were used to build an OPLS-DA statistical model capable of accurately distinguishing Ctrl, MCI and MCI_AD. The model accurately distinguished (R2 = 99.1%; Q2 = 97%) those MCI patients who later went on to develop AD. S-plots were used to shortlist ions of interest which were responsible for explaining the maximum amount of variation between patient groups. Metabolite database searching and pathway enrichment analysis indicated disturbances in 22 biochemical pathways, and excitingly it discovered two interlinked areas of metabolism (polyamine metabolism and L-Arginine metabolism) were differentially disrupted in this well-defined clinical cohort. The optimised untargeted HRMS methods described herein not only demonstrate that it is possible to distinguish these pathologies in human blood but also that MCI patients 'at risk' from AD could be predicted up to 2 years earlier than conventional clinical diagnosis. Blood-based metabolite profiling of plasma from memory clinic patients is a novel and feasible approach in improving MCI and AD diagnosis and, refining clinical trials through better patient stratification.